KURA ONCOLOGY, INC.

(KURA)
  Report
Delayed Nasdaq  -  05/27 04:00:01 pm EDT
13.51 USD   +7.65%
05/26Kura Oncology to Participate in Three Upcoming Investor Conferences
AQ
05/04KURA ONCOLOGY : Q1 Earnings Snapshot
AQ
05/04KURA ONCOLOGY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Kura Oncology Initiates Dosing in Phase 1/2 Clinical Trial of Head, Neck Cancer Combo Therapy

12/16/2021 | 11:12am EDT


© MT Newswires 2021
Stocks mentioned in the article
ChangeLast1st jan.
KURA ONCOLOGY, INC. 7.65% 13.51 Delayed Quote.-3.50%
NOVARTIS AG -0.80% 87.12 Delayed Quote.8.52%
All news about KURA ONCOLOGY, INC.
05/26Kura Oncology to Participate in Three Upcoming Investor Conferences
AQ
05/04KURA ONCOLOGY : Q1 Earnings Snapshot
AQ
05/04KURA ONCOLOGY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RE..
AQ
05/04TRANSCRIPT : Kura Oncology, Inc., Q1 2022 Earnings Call, May 04, 2022
CI
05/04Kura Oncology Reports First Quarter 2022 Financial Results
AQ
05/04Kura Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/27Kura Oncology to Report First Quarter 2022 Financial Results
AQ
04/08Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergenc..
AQ
04/08Kura Oncology, Inc. Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Em..
CI
03/15TRANSCRIPT : Kura Oncology, Inc. Presents at Barclays Global Healthcare Conference 2022, M..
CI
More news
Analyst Recommendations on KURA ONCOLOGY, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -148 M - -
Net cash 2022 322 M - -
P/E ratio 2022 -6,15x
Yield 2022 -
Capitalization 900 M 900 M -
EV / Sales 2022 -
EV / Sales 2023 33,6x
Nbr of Employees 117
Free-Float 94,2%
Chart KURA ONCOLOGY, INC.
Duration : Period :
Kura Oncology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KURA ONCOLOGY, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 13,51 $
Average target price 35,88 $
Spread / Average Target 166%
EPS Revisions
Managers and Directors
Troy E. Wilson Chairman, President, CEO & Chief Financial Officer
Mollie Leoni Senior Vice President-Clinical Development
Stephen Dale Chief Medical Officer
Kathleen Ford Chief Operating Officer
Faheem Hasnain Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
KURA ONCOLOGY, INC.-3.50%900
GILEAD SCIENCES, INC.-10.76%81 280
REGENERON PHARMACEUTICALS, INC.9.70%74 647
VERTEX PHARMACEUTICALS24.65%70 008
BIONTECH SE-35.24%40 574
WUXI APPTEC CO., LTD.-22.01%39 958